Patents by Inventor Shanchun Wang

Shanchun Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12358891
    Abstract: The present application relates to the field of medicine, and relates to crystals of quinoline derivatives, and in particular, to crystals of a quinoline derivative anhydride and a solvate, as well as a method for preparing the crystals, pharmaceutical compositions containing the crystals, and a use thereof in the field of medicine. The present application further provides a preparation method therefor, which has a high yield, has mild crystallization conditions, is suitable for industrial production, and may better meet the needs of the pharmaceutical industry.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: July 15, 2025
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Xiquan Zhang, Shanchun Wang, Wenjun Geng, Yanlong Liu, Huihui Zhang, Fei Liu, Shanliang Zhu, Xinlu Li, Rui Zhao, Hongmei Gu
  • Patent number: 12319689
    Abstract: Disclosed is a methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor; specifically disclosed are a compound of formula I, a stereoisomer or pharmaceutically acceptable salt of same, a preparation method therefor, and a pharmaceutical composition comprising the compound. Also disclosed are uses of the compound and of the pharmaceutical composition comprising the compound in treating anti-apoptotic protein BCL-2-related diseases such as cancer.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: June 3, 2025
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Fei Liu, Yanlong Liu, Hongjiang Xu, Xiquan Zhang, Shanchun Wang, Jianqing Zhang, Weiwei Feng, Bin Wang, Jinan Wang, Yubing Wang, Xujing Tang, Quandeng Nie
  • Patent number: 11554115
    Abstract: The present invention provides a quinoline derivative for treating triple-negative breast cancer and use thereof in preparing a pharmaceutical composition for treating a tumor.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: January 17, 2023
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Xin Tian, Peng Lv, Ling Yang, Xiangjian Wang, Xiquan Zhang, Shanchun Wang, Xunqiang Wang, Hai Jiang
  • Patent number: 11534398
    Abstract: The present invention belongs to the field of medicine, relates to an inhaled preparation of isoglycyrrhizic acid or a salt thereof, and in particular relates to an inhaled preparation of magnesium isoglycyrrhizinate and the use thereof in preparing drugs for treating respiratory system diseases.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: December 27, 2022
    Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Inventors: Hongmei Gu, Shanchun Wang, Xiquan Zhang, Lei Huang, Hongjiang Xu, Wei Song, Ping Dong, Zhongying Sun, Ying Zhang, Deyang Chen
  • Patent number: 11419862
    Abstract: The present invention provides a quinoline derivative for the treatment of nasopharyngeal carcinoma and use thereof in preparation of a pharmaceutical composition for tumor treatment.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: August 23, 2022
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Shanchun Wang, Jun Shen, Xi Han, Xunqiang Wang, Shaonan Tang, Shuqing Cao, Xiquan Zhang, Hao Yu, Maoqiong Pan, Ping Xu, Chengqian Wang
  • Publication number: 20220220110
    Abstract: Disclosed is a methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor; specifically disclosed are a compound of formula I, a stereoisomer or pharmaceutically acceptable salt of same, a preparation method therefor, and a pharmaceutical composition comprising the compound. Also disclosed are uses of the compound and of the pharmaceutical composition comprising the compound in treating anti-apoptotic protein BCL-2-related diseases such as cancer.
    Type: Application
    Filed: May 22, 2020
    Publication date: July 14, 2022
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Fei LIU, Yanlong LIU, Hongjiang XU, Xiquan ZHANG, Shanchun WANG, Jianqing ZHANG, Weiwei FENG, Bin WANG, Jinan WANG, Yubing WANG, Xujing TANG, Quandeng NIE
  • Publication number: 20220211694
    Abstract: Provided is an application of a compound, 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxy quinolin-7-yl]oxy]methyl]cyclopropylamine, in preparation of a medicament for the treatment of head and neck cancer, and an application of a pharmaceutical composition of the compound combined with a second therapeutic drug in the preparation of a medicament for the treatment of head and neck cancer. The head and neck cancer can also be nasopharyngeal cancer.
    Type: Application
    Filed: May 25, 2020
    Publication date: July 7, 2022
    Inventors: Shanchun WANG, Bin ZHANG, Weifeng WANG, Ping XU
  • Publication number: 20220175759
    Abstract: The present invention relates to the field of biomedicine and relates to a combined pharmaceutical composition used for treating small cell lung cancer, the composition comprising an anti-PD-L1 antibody and anlotinib, and having good anti-small cell lung cancer activity.
    Type: Application
    Filed: March 13, 2020
    Publication date: June 9, 2022
    Inventors: Shanchun WANG, Xunqiang WANG, Ding YU, Wenwen LIU, Chao SHU, Mengxue FAN
  • Publication number: 20220098172
    Abstract: The present application relates to the field of medicine, and relates to crystals of quinoline derivatives, and in particular, to crystals of a quinoline derivative anhydride and a solvate, as well as a method for preparing the crystals, pharmaceutical compositions containing the crystals, and a use thereof in the field of medicine. The present application further provides a preparation method therefor, which has a high yield, has mild crystallization conditions, is suitable for industrial production, and may better meet the needs of the pharmaceutical industry.
    Type: Application
    Filed: July 31, 2020
    Publication date: March 31, 2022
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Xiquan ZHANG, Shanchun WANG, Wenjun GENG, Yanlong LIU, Huihui ZHANG, Fei LIU, Shanliang ZHU, Xinlu LI, Rui ZHAO, Hongmei GU
  • Publication number: 20220031689
    Abstract: The present application relates to the field of medicine, and provided thereby is a quinoline derivative used for treating small cell lung cancer. The 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof as provided by the present application may be used for the treatment of small cell lung cancer, especially for patients suffering from refractory relapsed small cell lung cancer, which may significantly prolong the survival time thereof; in addition, the therapeutic effect on brain metastatic small cell lung cancer is also very significant.
    Type: Application
    Filed: September 18, 2019
    Publication date: February 3, 2022
    Inventors: Shanchun WANG, Ding YU, Xunqiang WANG, Bangan PENG, Lu LIU, Jie DAI, Hang ZHOU, Yadong MIAO
  • Publication number: 20220002290
    Abstract: Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.
    Type: Application
    Filed: October 29, 2019
    Publication date: January 6, 2022
    Inventors: Fei Liu, Weiwei Feng, Bin Wang, Hongjiang Xu, Jinan Wang, Xiquan Zhang, Shanchun Wang, Yanlong Liu, Jianqing Zhang, Yiyan Yao, Xujing Tang, Wei Shi, Hongying Zhang, Yang Li, Song Tang, Yizhong Zhu, Limin Liu, Hongmei Gu, Ling Yang
  • Patent number: 11203586
    Abstract: An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation induced cancer.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: December 21, 2021
    Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.
    Inventors: Li Zhu, Yanqing Yang, Liguang Dai, Xiaowei Duan, Zhao Yang, Hui Zhang, Yuandong Hu, Yong Peng, Yongxin Han, Rui Zhao, Xin Tian, Shanchun Wang
  • Patent number: 11111240
    Abstract: Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: September 7, 2021
    Assignees: Chai Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.
    Inventors: Li Zhu, Xiaowei Duan, Liguang Dai, Zhao Yang, Yanqing Yang, Hui Zhang, Yuandong Hu, Yong Peng, Yongxin Han, Rui Zhao, Xin Tian, Shanchun Wang
  • Publication number: 20210155610
    Abstract: An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation induced cancer.
    Type: Application
    Filed: March 22, 2017
    Publication date: May 27, 2021
    Inventors: Li ZHU, Yanqing YANG, Liguang DAI, Xiaowei DUAN, Zhao YANG, Hui ZHANG, Yuandong HU, Yong PENG, Yongxin HAN, Rui ZHAO, Xin TIAN, Shanchun WANG
  • Publication number: 20210047314
    Abstract: Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.
    Type: Application
    Filed: March 22, 2017
    Publication date: February 18, 2021
    Inventors: Li ZHU, Xiaowei DUAN, Liguang DAI, Zhao YANG, Yanqing YANG, Hui ZHANG, Yuandong HU, Yong PENG, Yongxin HAN, Rui ZHAO, Xin TIAN, Shanchun WANG
  • Patent number: 10888559
    Abstract: The present application provides a quinoline derivative against non-small cell lung cancer. 1-[[[4-(4-fluoro-2-methyl)-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of non-small cell lung cancer, and relative to placebo, can significantly improve non-small cell lung cancer patients without progression of survival. 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclo propylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of lung adenocarcinoma, and relative to placebo, can significantly improve lung adenocarcinoma patients without progression of survival.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: January 12, 2021
    Inventors: Xunqiang Wang, Yadong Miu, Min Zhou, Shanchun Wang, Ling Yang, Wei Shi
  • Publication number: 20200405709
    Abstract: The present invention provides a quinoline derivative for treating triple-negative breast cancer and use thereof in preparing a pharmaceutical composition for treating a tumor.
    Type: Application
    Filed: March 13, 2019
    Publication date: December 31, 2020
    Inventors: Xin TIAN, Peng LV, Ling YANG, Xiangjian WANG, Xiquan ZHANG, Shanchun WANG, Xunqiang WANG, Hai JIANG
  • Publication number: 20200368158
    Abstract: The present invention belongs to the field of medicine, relates to an inhaled preparation of isoglycyrrhizic acid or a salt thereof, and in particular relates to an inhaled preparation of magnesium isoglycyrrhizinate and the use thereof in preparing drugs for treating respiratory system diseases.
    Type: Application
    Filed: August 7, 2020
    Publication date: November 26, 2020
    Inventors: Hongmei GU, Shanchun WANG, Xiquan ZHANG, Lei HUANG, Hongjiang XU, Wei SONG, Ping DONG, Zhongying SUN, Ying ZHANG, Deyang CHEN
  • Publication number: 20200352932
    Abstract: The present invention provides a quinoline derivative for the treatment of nasopharyngeal carcinoma and use thereof in preparation of a pharmaceutical composition for tumor treatment.
    Type: Application
    Filed: July 23, 2020
    Publication date: November 12, 2020
    Inventors: Shanchun WANG, Jun SHEN, Xi HAN, Xunqiang WANG, Shaonan TANG, Shuqing CAO, Xiquan Zhang, Hao YU, Maoqiong PAN, Ping XU, Chengqian WANG
  • Patent number: 10829492
    Abstract: Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: November 10, 2020
    Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., CENTAURUS BIOPHARMA CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.
    Inventors: Li Zhu, Yuandong Hu, Wei Wu, Liguang Dai, Xiaowei Duan, Yanqing Yang, Yinghui Sun, Yongxin Han, Yong Peng, Fansheng Kong, Hong Luo, Ling Yang, Hongjiang Xu, Meng Guo, Zhaobai Zhong, Shanchun Wang